-
公开(公告)号：WO2012068355A2
公开(公告)日：2012-05-24
申请号：PCT/US2011/061158
申请日：2011-11-17
Applicant: TUFTS MEDICAL CENTER, INC. , GALPER, Jonas, B.
Inventor： GALPER, Jonas, B.
CPC classification number: A61K35/74 , A61K31/739 , A61K38/08 , A61K38/10 , A61K38/164 , G01N33/505 , G01N33/5055 , G01N33/6893 , G01N2800/329 , G01N2800/52
Abstract: Methods for treating aortic aneurysm, such as abdominal aortic aneurysm (AAA), by either activating TLR2 signaling or suppressing TLR4 signaling and methods for diagnosing aortic aneurysm and assessing aortic aneurysm treatment efficacy in, e.g., a laboratory animal, based on the amount of an immune cell population such as the regulatory T cell population and/or the M1 and M2 macrophage populations. Also disclosed herein are pharmaceutical compositions for use in treating aortic aneurysm, the composition comprising a TLR2 agonist, a TLR4 antagonist, or a combination thereof.
Abstract translation: 用于通过激活TLR2信号传导或抑制TLR4信号的治疗主动脉瘤，例如腹主动脉瘤（AAA）的方法以及用于诊断主动脉瘤的方法和基于实验室动物的量来评价主动脉瘤治疗功效的方法 免疫细胞群体，例如调节性T细胞群体和/或M1和M2巨噬细胞群体。 本文还公开了用于治疗主动脉瘤的药物组合物，所述组合物包含TLR2激动剂，TLR4拮抗剂或其组合。
-
公开(公告)号：WO2012068355A3
公开(公告)日：2012-07-26
申请号：PCT/US2011061158
申请日：2011-11-17
Applicant: TUFTS MEDICAL CT INC , GALPER JONAS B
Inventor： GALPER JONAS B
CPC classification number: A61K35/74 , A61K31/739 , A61K38/08 , A61K38/10 , A61K38/164 , G01N33/505 , G01N33/5055 , G01N33/6893 , G01N2800/329 , G01N2800/52
Abstract: Methods for treating aortic aneurysm, such as abdominal aortic aneurysm (AAA), by either activating TLR2 signaling or suppressing TLR4 signaling and methods for diagnosing aortic aneurysm and assessing aortic aneurysm treatment efficacy in, e.g., a laboratory animal, based on the amount of an immune cell population such as the regulatory T cell population and/or the M1 and M2 macrophage populations. Also disclosed herein are pharmaceutical compositions for use in treating aortic aneurysm, the composition comprising a TLR2 agonist, a TLR4 antagonist, or a combination thereof.
Abstract translation: 通过激活TLR2信号传导或抑制TLR4信号传导治疗主动脉瘤如腹主动脉瘤（AAA）的方法，以及用于诊断主动脉瘤和评估例如实验动物中的主动脉瘤治疗功效的方法，其基于 免疫细胞群如调节性T细胞群和/或M1和M2巨噬细胞群。 本文还公开了用于治疗主动脉瘤的药物组合物，所述组合物包含TLR2激动剂，TLR4拮抗剂或其组合。
-
3.发明申请USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION 审中-公开HMGCoA还原抑制剂在预防病因与依赖于新生血管疾病相关的疾病中的应用
公开(公告)号：WO0067737A9
公开(公告)日：2002-02-21
申请号：PCT/US0012309
申请日：2000-05-05
Applicant: BRIGHAM & WOMENS HOSPITAL , GALPER JONAS B , KONG DEQUAN , IRUELA ARISPE LUISA , PARK HO JIN
Inventor： GALPER JONAS B , KONG DEQUAN , IRUELA-ARISPE LUISA , PARK HO-JIN
IPC: A61K31/00 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , C12Q1/26 , G01N33/50 , A61K31/404 , A61P9/10 , A61P15/18 , A61P17/06 , A61P19/02 , A61P27/02 , A61P35/00 , A61P35/04
CPC classification number: A61K31/404 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , C12Q1/26 , G01N33/5011 , G01N2500/00
Abstract: HMGCoA reductase inhibitors have a well-known mechanism in controlling cholesterol metabolism. HMGCoA reductase inhibitors also have a less well-known effect on gene expression. This invention provides a new use for HMGCoA reductase inhibitors in the treatment of diseases whose pathogenesis is dependent on neovascularization. HMGCoA reductase inhibitors are administered at anti-angiogenic therapeutic doses for the treatment of primary and metastatic tumors, inflammatory processes involving new vessel formation, diabetic retinopathy, rheumatoid arthritis, and atherosclerosis. HMGCoA reductase inhibitors affect the expression of genes through interference with the function of small GTP binding proteins (such as Rho). Because of the low incidence of side effects with these agents, HMGCoA reductase inhibitors could also be taken prophylactically to prevent the development of diseases in which the pathogenesis is caused by neovascularization.
Abstract translation: HMGCoA还原酶抑制剂具有控制胆固醇代谢的众所周知的机制。 HMGCoA还原酶抑制剂对基因表达也具有较不着名的作用。 本发明提供HMGCoA还原酶抑制剂治疗其发病机制依赖于新血管形成的疾病的新用途。 HMGCoA还原酶抑制剂以抗血管生成治疗剂量施用，用于治疗原发性和转移性肿瘤，涉及新血管形成的炎症过程，糖尿病性视网膜病变，类风湿性关节炎和动脉粥样硬化。 HMGCoA还原酶抑制剂通过干扰小GTP结合蛋白（如Rho）的功能影响基因的表达。 由于这些药物的副作用发生率低，也可以预防HMGCoA还原酶抑制剂，以防止由新生血管形成引起发病的疾病的发展。
-
4.发明申请USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION 审中-公开HMGCoA还原抑制剂在预防病变与依赖于新生血管疾病的预防中的应用
公开(公告)号：WO0067737A2
公开(公告)日：2000-11-16
申请号：PCT/US0012309
申请日：2000-05-05
Applicant: BRIGHAM & WOMENS HOSPITAL , GALPER JONAS B , KONG DEQUAN
Inventor： GALPER JONAS B , KONG DEQUAN
IPC: A61K31/00 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , C12Q1/26 , G01N33/50
CPC classification number: A61K31/404 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , C12Q1/26 , G01N33/5011 , G01N2500/00
Abstract: HMGCoA reductase inhibitors have a well-known mechanism in controlling cholesterol metabolism. HMGCoA reductase inhibitors also have a less well-known effect on gene expression. This invention provides a new use for HMGCoA reductase inhibitors in the treatment of diseases whose pathogenesis is dependent on neovascularization. HMGCoA reductase inhibitors are administered at anti-angiogenic therapeutic doses for the treatment of primary and metastatic tumors, inflammatory processes involving new vessel formation, diabetic retinopathy, rheumatoid arthritis, and atherosclerosis. HMGCoA reductase inhibitors affect the expression of genes through interference with the function of small GTP binding proteins (such as Rho). Because of the low incidence of side effects with these agents, HMGCoA reductase inhibitors could also be taken prophylactically to prevent the development of diseases in which the pathogenesis is caused by neovascularization.
Abstract translation: HMGCoA还原酶抑制剂在控制胆固醇代谢中具有众所周知的机制。 HMGCoA还原酶抑制剂对基因表达也具有不太公知的作用。 本发明提供HMGCoA还原酶抑制剂治疗其发病机制依赖于新血管形成的疾病的新用途。 HMGCoA还原酶抑制剂以抗血管生成治疗剂量施用，用于治疗原发性和转移性肿瘤，涉及新血管形成的炎症过程，糖尿病性视网膜病变，类风湿性关节炎和动脉粥样硬化。 HMGCoA还原酶抑制剂通过干扰小GTP结合蛋白（如Rho）的功能影响基因的表达。 由于这些药物的副作用发生率低，也可以预防HMGCoA还原酶抑制剂，以防止由新生血管形成引起发病的疾病的发展。
-
-
-
Search Results
4
records
(took 0.011 seconds)
